Index

Note: Page numbers of article titles are in **boldface** type.

A

Acne, relief of, oral contraception and, 480–483
Antihypertensive medications, and risk factor for cardiovascular disease, 545
Aspirin, and risk factor for cardiovascular disease, 545

B

Bacterial vaginosis, and vaginal and vulvar disorders, compared, 556–557
Barrier methods of contraception, 513, 514
Bartholin’s gland, disorders of, 561
**BRCA1** and **BRCA2** gene mutations, breast cancer screening in, 457
Breast cancer screening, 451–467
  - breast self-examination for, 452
  - candidates for, 451–452
  - clinical breast examination for, 453
  - communication after, 461–462
  - communication prior to, 461–462
  - computer-aided detection for, 454
  - digital breast tomosynthesis for, 454–455
  - digital infrared thermal imaging for, 455–457
  - frequency of, 452
  - imaging in, 453–457
  - in **BRCA1** and **BRCA2** gene mutations, 457
  - in lifetime risk of breast cancer greater than 20%, 457–458
  - interpretation of results of, 461
  - mamography for, 453, 454, 456
  - methods of, 452–457
  - MRI for, 453, 455
  - potential benefits of, 458–459
  - potential risks of, 459–461
  - ultrasound for, 453
  - use of, 451

C

Candidiasis, vulvovaginal, 559–560
Cardiovascular disease, atherosclerotic, disorders increasing risk of, 540
  - number needed to harm, 536
  - number needed to treat, 536
  - screening for, 547
  - chronic kidney disease and, 540
  - definitions of, 535
Cardiovascular (continued)
   introduction to, 536–537
   obesity and, 540
   prevention of, 536
   rheumatic diseases and, 540
   risk factors for, nonpharmacologic modification of, 546
      pharmacologic modification of, 543–546
   unique to women, 541
   sleep apnea and, 540
Cardiovascular risk factors and disease, in women, 535–552
Cervical cancer, prevention of, 469–477
   screening for, 470–472
      after treatment of cervical intraepithelial neoplasia, 473–474
      age to enter, 472
      age to exit, 473
      in human immunodeficiency-virus-positive patients, 474
      in total hysterectomy, 473
      in vaccinated women, 474
      intervals for, 472–473
Cognitive decline, statin-induced, 544
Computer-aided detection, for breast cancer screening, 454
Contraception, emergency options for, 515–516
   fertility awareness as, 515
   form(s) of, barrier methods as, 513, 514
      injectable progestin as, 512–513
      patch as, 513
      sterilization as, 511–512
      vaginal ring as, 513
      withdrawal as, 513
   impact on sexual function and desire, 515
   methods of, 506, 508
   options for, beyond oral contraceptive pills, 506, 507
Contraceptives, long-acting reversible, intrauterine devices and subdermal implants as, 506–511

D
Death, cardiovascular disease-related causes of, 539
   causes in women, 537
Depressive and anxiety disorders, in childbearing years, 669–670
Dermatitis, allergic contact, 565–567
Diabetes, pregestational, in childbearing years, 666–667
Dysmenorrhea, treatment of, 483

E
Estrogen, vaginal, for treatment of vulvovaginal atrophy of menopause, 528–529, 531

F
Fertility awareness, as contraceptive method, 515
Gastrointestinal disorders, functional, in women veterans, 655–656
Genetic disease, and prior poor pregnancy outcomes, screening for, in
preconception care, 676
Genitourinary syndrome, of menopause, 527–530

Heart disease, chronic, patient counseling in, 540
risk factor assessment for, 537, 539
Hepatitis C virus infection, chronic, in pregnancy, 578
in women, prevalence and management of, 575–586
comorbid alcohol use and, 578
epidemiology and management of, 576
natural history of, 577–578
nonpharmacologic management of, 581
pharmacologic management of, 578–581
premenopausal, treatment of, 579–581
psychosocial considerations in, 581–584
screening for, 577
transmission of, 576–577
Herpes simplex virus, genital, 563–564
Hip fractures, 593, 595
Hormonal oral contraception, 479, 480, 481
Hormonal treatment, for menopause, 524, 525, 526
contraindications to, 526
risks of, 525–526
Human papillomavirus, in cervical cancer, 469
testing for, and Papanicolaou(Pap) test, 470–472
Human papillomavirus vaccines, 470
Hyperglycemia/diabetes, statin-induced, 544–545
Hypertension, in childbearing years, 667–668

Intimate partner violence, 629–649
adolescent health and, 638
age and, 631
definition of, 629–630
during pregnancy, 633, 636–637
gender and, 631
health consequences of, 633–639
homicide as, 639
in health care settings, 632–633
in increased health risk behaviors, 634–635
intervention in, 640–644
legal issues in, 644
medical consequences of, 633–634
mental health consequences of, 635–636
patterns of, 630
Intimate (continued)
   physical injury due to, 638
   prevalence of, 630–632
   psychological aggression as, 630
   race and, 631
   safety assessment in, 641–642
   screening in, 639–640, 641
   self-determination in, 644–645
   sexual orientation and, 631–632
   socioeconomic status and, 632
Intrauterine devices, and other forms of contraception, 505–520
   and subdermal implants, 509
      as long-acting reversible contraceptives, 506–511

K
Kidney disease, chronic, cardiovascular disease and, 540

L
Lichen planus, 569–571
   vulvar, 621–623, 624
Lichen sclerosis, 572–573
Lichen simplex chronicus, 568–569

M
Magnetic resonance imaging, for breast cancer screening, 453, 455
Mammography, for breast cancer screening, 453, 454, 456
Medical conditions, chronic, in childbearing years, 671
Medications, with teratogenic effects, 672–673
Menopause, 521–534
   as risk factor for cardiovascular disease, 541
   cognitive function during, 531
   definition of, 521–522
   depression during, 530–531
   genitourinary syndrome of, 527–530
   hormonal treatment of, 524, 525–526
   physiology of, 522
   urinary symptoms of, 529–530
   vasomotor symptoms of, 522–523
      causes of, 523
      evaluation of, 523
      hormonal treatment for, 524, 525, 526
      lifestyle modifications in, 524
      nonhormonal treatment for, 526–527
      nonprescription treatment for, 527
      treatment of, 524–527
Myalgia, statin-induced, 544
Myopathy, statin-induced, 544

O

Obesity, cardiovascular disease and, 540
  in childbearing years, 668–669
Oral contraception, 479–503
  acne relief and, 480–483
  combination, cyclic versus continuous use of, 490–491
  considerations for special populations, 494–496
  development of, 479
  generic versus brand name drugs for, 489
  hormonal, 479
    ingredients and formulations for, 480, 481
    improving adherence to, 492–493
    medication interactions with, 489
    options for, choosing between, 490
    patient counseling for, 492–494
    perimenopause, 495–496
    physical examination and, 489
    postpartum, 487, 495
    side effects of, 492
    venous thromboembolism risk and, 488–489
Oral contraception pills, COCs for, 480, 482, 490
  for pregnancy prevention, 480
  history and safety of, 480
  MEC for, 480, 482
  missed, advice for, 493
  noncontraceptive health benefits of, 480–483
  prescribing of, 488–490
  progestin-only, 480
  risks of, and contraindications to, 483–488
Oral contraceptives, as risk factor for cardiovascular disease, 543
Ospemifene (Osphena), for treatment of vulvar vaginitis atrophy of menopause, 529

Osteoporosis, 587–606
  diagnostic evaluation of, 594–596, 597
  fractures due to, 587–588
    clinical syndromes of, 593–594
  incidence of, 587
  management of, 596–601
  medications contributing to, 591
  monitoring of, 602–603
  nonpharmacologic treatments for, 601
  osteoporotic specific medications in, indications to prescribe, 597
  pathophysiology of, 588–589
  pharmacologic treatments for, 598–601
  prevention of, 602–603
Osteoporosis (continued)
   risk factors for, 589–590, 591
   screening for, 590–592, 593
   secondary causes of, 590
   terms used in, 588

P
Papanicolaou(Pap) test, and testing for human papillomavirus, 470–472
Patch, contraceptive, 513
Pelvic pain, causes of, 618
Polycystic ovary syndrome, 536
   as risk factor for cardiovascular disease, 541
Post-traumatic stress disorder, in women veterans, 657–659
Preconception care, 674–676
   and reproductive planning, in primary care, 663–682
   risk factors in, 674–675
   screening for prior poor pregnancy outcomes and genetic disease in, 676
Pregnancy, prior poor outcomes of, and genetic disease, screening for, in
   preconception care, 676
Pregnancy complications, as risk factor for cardiovascular disease, 541–542
Premenstrual dysphoric disorder, 483
Premenstrual syndrome, 483

R
Reproductive planning, 664–666
   and preconception care, in primary care, 663–682
   optimizing of chronic conditions in, 666–671
   questions in, 664–665
Rhabdomyolysis, statin-induced, 544
Rheumatic diseases, cardiovascular disease and, 540

S
Serotonin reuptake inhibitors, selective, in sexual dysfunction, 614–615
Sexual dysfunction, female, 607–628
   arousal disorders and, 615–617
   classification of, 606–610
   desire disorders and, 610–615
   orgasm disorders and, 617
   pain disorders and, 617–625
Sexual response cycle, 607–608
   cyclical, 608
Sexual trauma, military, in women veterans, 657–659
Sleep apnea, cardiovascular disease and, 540
Statin(s), adverse effects of, 543–544
   and niacin, as risk factors for cardiovascular disease, 545
   relative potency of, 543
   use in older women, 538, 539
Stroke risk factors, and risk factor for cardiovascular disease, 542
Subdermal implants, 509
and intrauterine devices, as long-acting reversible contraceptives, 506–511

T
Testosterone therapy, for hypoactive sexual desire disorder, 611–614
Thermal imaging, digital infrared, for breast cancer screening, 455–457
Tomosynthesis, digital breast, for breast cancer screening, 454–455
Trichomoniasis, 558–559
Triglycerides, as risk factor for cardiovascular disease, 545

U
Ultrasound, for breast cancer screening, 453

V
Vaginal and vulvar disorders, and bacterial vaginosis, compared, 556–557
causes of, 557
common, 553–574
diagnostic testing and imaging in, 555, 556
differential diagnosis of, 556
future considerations in, 553
patient history in, 553–554
physical examination in, 555
recurrence of, prevention and management of, 557–558
symptoms of, 554
Vaginal ring, as form of contraception, 513
Vaginitis, atrophic, 560–561, 619–621
Venous thromboembolism, risk of, oral contraception and, 488–489
Vertebral compression fractures, 593–594, 595
Veterans, women, as different from male veterans, 652
care of, 651–662
outside of VA system, 652–653, 654
conditions diagnosed in, 652, 653
functional and pain disorders in, 656–657
functional gastrointestinal disorders in, 655–656
homelessness among, 660
mental health screening of, 658, 659
military cultural competency and, 653–655, 656
number of, 652
post-traumatic stress disorder and military sexual trauma in, 657–659
Vulva, anatomy of, 555
hygiene guidelines, 565
Vulvar intraepithelial neoplasia/condyloma, 561–562
Vulvodynia, 623, 625
Vulvovaginal atrophy, of menopause, 527–528
genitourinary symptoms of, 528
Vulvovaginal (continued)
   symptoms of, 529
   treatment of, 528–529
   nonprescription, 528
   ospemifene(osphena) for, 529
   vaginal estrogen for, 528–529, 531
Vulvovaginal candidiasis, 559–560

W

Women, diseases and conditions of. See specific diseases and conditions.